Actinium Pharmaceuticals, Inc.

4:00 PM - 4:15 PM, Tuesday, June 4, 2019 ・ Theater 1
Actinium Pharmaceuticals Inc. is focused on improving patient access and outcomes to cellular therapies such as bone marrow transplant (BMT) and CAR-T with its proprietary, chemotherapy free or sparing, targeted conditioning technology. Actinium is the only company with a multi-disease, multi-target, drug development pipeline focused on targeted conditioning. Its targeted conditioning technology is enabled by ARC’s or Antibody Radiation Conjugates that combine the targeting ability of monoclonal antibodies with the cell killing ability of radioisotopes. Actinium’s pipeline of clinical-stage targeted conditioning ARCs target the antigens CD45 and CD33 for patients with a broad range of hematologic malignancies including acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and multiple myeloma (MM), acute lymphoblastic leukemia (ALL), Hodgkin’s lymphoma and Non-Hodgkin’s lymphoma.
Ticker:
ATNM
Exchange:
NYSE AMERICAN
Company Type:
Company Website:
Company HQ State:
New York
Company HQ Country:
United States
Year Founded:
2000
Main Therapeutic Focus:
Lead Product in Development:
Iomab-B
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
3
Speaker
photo
Chief Business Officer
Actinium Pharmaceuticals, Inc.